Company intelligence / Profile preview

Marchant Securities

Toronto, Ontario, Canada

Ownership: Private
Employees: ~130
Development stage: Other

Overview

Greybrook Securities (formerly Marchant Securities) is the capital markets division of Greybrook Capital, a North American private equity firm based in Toronto. The firm specializes in raising capital for and managing investments in the healthcare and real estate sectors. Through its healthcare arm, Greybrook Health, the company has built a significant portfolio of transformative healthcare businesses, including Greenbrook TMS, TearLab, and Neupath Health. Greybrook focuses on identifying and scaling innovative companies in medical devices, diagnostics, and healthcare services to improve patient outcomes.

Therapeutic areas: PsychiatryNeurologyOphthalmology
Modalities: DeviceDiagnosticsHealthcare ServicesNutraceuticals
Industry: Investors

Partnerships

1315 CapitalBioStar CapitalMadryn Asset Management

Beyond the preview

Go deeper on Marchant Securities.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marchant Securities.

Explore the full profile